Prosecution Insights
Last updated: April 19, 2026
Application No. 18/012,364

BRANCHED LIPID COMPOUDS

Non-Final OA §DP
Filed
Dec 22, 2022
Examiner
CHENG, KAREN
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ena Respiratory Pty Ltd.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
2y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
517 granted / 677 resolved
+16.4% vs TC avg
Strong +28% interview lift
Without
With
+27.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
34 currently pending
Career history
711
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
27.4%
-12.6% vs TC avg
§102
21.5%
-18.5% vs TC avg
§112
30.7%
-9.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 677 resolved cases

Office Action

§DP
DETAILED ACTION Claims 1-4, 6-9, 11, 13-25 and 28-29 are currently pending in the instant application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I, drawn to claims 1-4, 6-9, 11, 13-16 and 28 with election of species PNG media_image1.png 198 464 media_image1.png Greyscale in the reply filed on 12/02/2025 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 17-25 and 29 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 12/02/2025. Priority PNG media_image2.png 88 386 media_image2.png Greyscale Information Disclosure Statement Applicant's Information Disclosure Statements filed on 08/14/2023, 01/23/2024, 05/09/2024, 12/18/2024 and 04/24/2025 have been considered. Please refer to Applicant's copies of the 1449 submitted herewith. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-4, 6-9, 11, 13-16 and 28 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 7-16, 19, 23-24 and 52 of copending Application No. 17/622,451 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because ‘451 teaches compounds and compositions comprising compounds of formula PNG media_image3.png 258 326 media_image3.png Greyscale . However, compounds 33-36 found in claim 23 of ‘451 correspond to compounds B9-B16 of instant claim 15. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. WO 2019/043604 (cited in IDS, filed 08/14/2023) teaches compounds such as PNG media_image4.png 204 274 media_image4.png Greyscale wherein X is PNG media_image5.png 44 554 media_image5.png Greyscale . However, ‘604 teaches linear alkyl groups (aka R24a, R24b, R25a, and R25b as H) rather than R24a and R25a as C1-C6 aliphatic groups or R24a and R24b and/or R25a and R25b together with the carbon atom to which they are attached to form a C3-8 cycloalkyl or 3-8 membered heterocyclyl group, which would result in either a branched or cyclic alkyl group chain. Similarly, WO 2018/176099 (cited in IDS, filed 08/14/2023) teaches compounds such as PNG media_image6.png 216 542 media_image6.png Greyscale having R24a, R24b, R25a, and R25b as H) rather than R24a and R25a as C1-C6 aliphatic groups or R24a and R24b and/or R25a and R25b together with the carbon atom to which they are attached to form a C3-8 cycloalkyl or 3-8 membered heterocyclyl group, which would result in either a branched or cyclic alkyl group chain. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAREN CHENG whose telephone number is (703)756-4699. The examiner can normally be reached M-F, 9AM-6PM PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached at 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAREN CHENG/Primary Examiner, Art Unit 1623 /ADAM C MILLIGAN/Supervisory Patent Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Dec 22, 2022
Application Filed
Feb 04, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595226
CARBONATE CONTAINING LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS
2y 5m to grant Granted Apr 07, 2026
Patent 12595266
PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS
2y 5m to grant Granted Apr 07, 2026
Patent 12583844
MATRIX METALLOPROTEINASE (MMP) INHIBITORS AND METHODS OF USE THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12553889
SMALL MOLECULES TARGETING THE INTRINSICALLY DISORDERED STRUCTURAL ENSEMBLE OF ALPHA-SYNUCLEIN PROTECT AGAINST DIVERSE ALPHA-SYNUCLEIN MEDIATED DYSFUNCTIONS
2y 5m to grant Granted Feb 17, 2026
Patent 12552755
CINNAMIC AMIDE DERIVATIVE HAVING FXR ACTIVATING EFFECT, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT, AND METHOD FOR PREPARING THE SAME
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+27.9%)
2y 3m
Median Time to Grant
Low
PTA Risk
Based on 677 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month